SynthesisHuman vaccines & immunotherapeutics2025
Cost-effectiveness modeling for gender-neutral human papillomavirus vaccines: A systematic literature review.
Synthesis in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Population-level impact of quadrivalent HPV vaccination in Brazil: a repeated cross-sectional study.NPJ vaccines · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gender-neutral vaccination (GNV) of human papillomavirus (HPV) may help reduce the transmission and incidence of HPV-related diseases. However, approximately 40 countries have implemented HPV GNV schedules. We systematically evaluated HPV GNV cost-effectiveness models from January 2008 to May 2024 using MEDLINE, Embase, and Cochrane to identify key drivers of cost-effectiveness results. Fifty-three publications were included, primarily from high-income countries. Vaccine coverage, price, protection duration, and discount rates impacted cost-effectiveness, with lower prices and protection against HPV-related diseases resulting in cost-effective results. Results in models that included adults (≥18 years) were mixed and dependent on price, inclusion of non-cervical HPV-related diseases, and age groups considered. We conclude that HPV GNV can be a cost-effective strategy for preventing HPV-related diseases. However, its cost-effectiveness is highly dependent on vaccine coverage, price, and inclusion of non-cervical HPV-related diseases in models. Further economic evaluations of HPV GNV in low- and middle-income countries are recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.